Biotech Values

[oc631]

For the sickest [GT3] patients the "new" option will be Sofo/PegRiba.

After reviewing the design of interferon-based NEUTRINO it's becoming clear GILD is a company that places profits above patient health. My suggestion that GT3 patients could use Sofo/PegRiba as a "new" option in 2014 isn't credible because GILD chose to intentionally exclude GT2 and GT3 patients from the NEUTRINO study.


Q: Why would GILD exclude GT2/GT3 and test GT1,4,5,6 in the NEUTRINO study?*


The design of this Phase-3 study is appalling even before we knew Sofo/Riba [oral] would only work in half of GT3 patients. Instead of giving all HCV patients the option of using Sofo/PegRiba as a second-line therapy they wrote GT2/GT3 patients out of the design. This design denies GT2 and GT3 treatment-failure patients early access to this interferon-based option which would work incredibly well in these two genotypes. Perhaps too well.


Now the oral GT3 option is a failure with nothing to fall back on.






*If someone on this MB or from Gilead Sciences can answer the question above I'm open to listening.